ArticleMikrochimica acta2026
Freeze-thaw-directed interfacial assembly of a gold nanoparticle/MXene electrochemical aptamer sensor for antibody-free myeloperoxidase detection.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
An electrochemical aptamer-based (E-AB) sensor for myeloperoxidase (MPO) was developed that combined a gold nanoparticle /MXene scaffold with freeze-thaw-directed aptamer immobilization and probe-density optimization. Unlike using nanocomposite amplification alone, this strategy regulates probe density and accessibility at the bioreceptor layer to improve target-coupled signal transduction. Using the same aptamer solution, the freeze-thaw method yielded 60.77% greater MPO-induced signal suppression and a 2.4-fold lower regression-derived limit of detection (LOD) than conventional incubation. After target incubation for 50 min at 4 °C, the sensor showed a linear response from 5.00 to 250.0 ng/mL in 1% plasma matrix (equivalent to 500 ~ 25,000 ng/mL in undiluted plasma), with an LOD of 4.15 ng/mL (equivalent to 415 ng/mL in undiluted plasma). These results illustrated that coupling conductive nanointerface design with aptamer-layer organization might provide a practical route for antibody-free and H
Indexed as
Identifiers
42758247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.